Laura Williams
Chief Tech/Sci/R&D Officer bij ARDELYX, INC.
Vermogen: 4 M $ op 29-02-2024
Profiel
Laura A.
Williams occupies the position of Chief Medical Officer for Ardelyx, Inc.
In the past Dr. Williams was Vice President-Clinical Development at Myovant Sciences, Inc. and Senior Vice President-Clinical Development at AMAG Pharmaceuticals, Inc.
She received a doctorate from the University of Iowa, an undergraduate degree from Mississippi State University and a graduate degree from the University of Washington.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ARDELYX, INC.
0.16% | 20-02-2024 | 380 138 ( 0.16% ) | 4 M $ | 29-02-2024 |
Actieve functies van Laura Williams
Bedrijven | Functie | Begin |
---|---|---|
ARDELYX, INC. | Chief Tech/Sci/R&D Officer | 01-01-2021 |
Eerdere bekende functies van Laura Williams
Bedrijven | Functie | Einde |
---|---|---|
AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2020 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 01-08-2017 |
IMARA | Director/Board Member | - |
Opleiding van Laura Williams
University of Washington | Graduate Degree |
Mississippi State University | Undergraduate Degree |
University of Iowa | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ARDELYX, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Imara, Inc.
Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |